The Manufacturers Life Insurance Company Purchases 8,066 Shares of CG Oncology, Inc. $CGON

The Manufacturers Life Insurance Company boosted its position in CG Oncology, Inc. (NASDAQ:CGON) by 6.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 136,544 shares of the company’s stock after buying an additional 8,066 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in CG Oncology were worth $9,241,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of CG Oncology by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock worth $249,111,000 after buying an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of CG Oncology by 116.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after buying an additional 1,854,386 shares during the period. State Street Corp raised its stake in CG Oncology by 46.4% during the 4th quarter. State Street Corp now owns 2,996,695 shares of the company’s stock worth $124,423,000 after buying an additional 950,028 shares during the period. Alliancebernstein L.P. lifted its holdings in CG Oncology by 15.0% during the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock worth $56,270,000 after acquiring an additional 281,637 shares in the last quarter. Finally, RTW Investments LP raised its position in shares of CG Oncology by 18.3% during the fourth quarter. RTW Investments LP now owns 2,012,127 shares of the company’s stock worth $83,544,000 after purchasing an additional 310,911 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

Insider Buying and Selling

In other news, Director Brian Guan-Chyun Liu purchased 371,085 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were purchased at an average cost of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the transaction, the director owned 1,886,236 shares of the company’s stock, valued at $126,132,601.32. The trade was a 24.49% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Leonard E. Post sold 5,000 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the completion of the sale, the director owned 5,000 shares of the company’s stock, valued at approximately $350,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 37,129 shares of company stock worth $2,663,817. Insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CGON shares. Wolfe Research began coverage on shares of CG Oncology in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Royal Bank Of Canada increased their target price on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Wedbush lifted their price target on shares of CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of CG Oncology in a research report on Wednesday, July 29th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $81.73.

CG Oncology Stock Down 2.9%

CGON stock opened at $69.15 on Tuesday. The company has a market cap of $6.10 billion, a price-to-earnings ratio of -29.68 and a beta of 0.23. CG Oncology, Inc. has a twelve month low of $23.65 and a twelve month high of $77.00. The business has a 50 day moving average price of $66.16 and a two-hundred day moving average price of $63.48.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. On average, equities research analysts anticipate that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.